Protein Summary
Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation (PARsylation) of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates PARsylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates PARsylation of TERF1, thereby contributing to the regulation of telomere length. Involved in centrosome maturation during prometaphase by mediating PARsylation of HEPACAM2/MIKI. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles. May be involved in spindle pole assembly through PARsylation of NUMA1. Stimulates 26S proteasome activity.
- ENST00000310430
- ENSP00000311579
- ENSG00000173273
- PARP5A
- PARPL
- TIN1
- TINF1
- TNKS1
- TIN1
- ARTD5
- PARPL
- TINF1
- TNKS1
- pART5
- PARP5A
- PARP-5a
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
biological process | 0.92 | ||
protein domain | 0.92 | ||
cellular component | 0.82 | ||
disease perturbation | 0.79 | ||
transcription factor binding site profile | 0.77 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 314.23 (req: < 5)
Gene RIFs: 75 (req: <= 3)
Antibodies: 343 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 314.23 (req: >= 5)
Gene RIFs: 75 (req: > 3)
Antibodies: 343 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 26
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 631
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 3